Summary of COVID-19 efzofitimod studies

1. Walker et al., A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)

32 patient efzofitimod late treatment RCT: 291% higher mortality (p=1), 24% longer hospitalization (p=0.53), and 11% worse recovery (p=1).
RCT 32 hospitalized COVID-19 patients showing no significant differences with efzofitimod.
Oct 2020, NCT04412668, https://clinicaltrials.gov/study/NCT04412668, https://c19p.org/walker2